Lymphoma development in patients with autoimmune and inflammatory disorders - What are the driving forcesα

Seminars in Cancer Biology

Volumn 24, Issue , 2014, Pages 61-70

  Baecklund, Eva ^a   Smedby, Karin E ^b   Sutton, Lesley Ann ^a   Askling, Johan ^b   Rosenquist, Richard ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antigen stimulation; Autoimmune disease; Chronic inflammation; Genetic events; Lymphoma; Risk factors

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

AUTOIMMUNE DISEASE; CARCINOGENESIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; HEREDITY; HODGKIN DISEASE; HUMAN; INFLAMMATORY DISEASE; LARGE CELL LYMPHOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; PATHOLOGY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ANTIGEN STIMULATION; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; GENETIC EVENTS; LYMPHOMA; RISK FACTORS;

ANTIGENS, CD27; ANTIGENS, CD80; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; LYMPHOMA; RISK FACTORS; SJOGREN'S SYNDROME; TUMOR MICROENVIRONMENT;

EID: 84892863959     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.12.001     Document Type: Review

References (135)

1. Smedby K.E., Baecklund E., Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006, 15:2069-2077.
2. Ekström Smedby K., Askling J., Mariette X., Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas - an update. J Intern Med 2008, 264(6):514-527.
3. Dias C., Isenberg D.A. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol 2011, 7(June (6)):360-368. [Review].
4. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692-701.
5. Hellgren K., Smedby K.E., Feltelius N., Baecklund E., Askling J. Do rheumatoid arthritis and lymphoma share risk factorsα A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum 2010, 62(May (5)):1252-1258.
6. Gridley G., Klippel J.H., Hoover R.N., Fraumeni J.F. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994, 120(January (1)):35-39.
7. Kauppi M., Pukkala E., Isomäki H. Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997, 8(March (2)):201-204.
8. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients. Arthritis Rheum 1998, 41(Suppl. 9):S188.
9. Baecklund E., Ekbom A., Sparén P., Feltelius N., Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J 1998, 317:180-181.
10. Löfström B., Backlin C., Sundström C., Ekbom A., Lundberg I.E. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 2007, 66(December (12)):1627-1632. [Epub 2007 May 21].
11. King J.K., Costenbader K.H. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin Rheumatol 2007, 26(September (9)):1491-1494. [Epub 2007 February 13].
12. Bernatsky S., Joseph L., Boivin J.F., Gordon C., Urowitz M., Gladman D., et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008, 67(January (1)):74-79. [Epub 2007 June 1].
13. Bernatsky S., Ramsey-Goldman R., Joseph L., Boivin J.F., Costenbader K.H., Urowitz M.B., et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis 2013, (January). [Epub ahead of print].
14. Bernatsky S., Ramsey-Goldman R., Rajan R., Boivin J.F., Joseph L., Lachance S., et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005, 64(October (10)):1507-1509.
15. Smedby K.E., Hjalgrim H., Askling J., Chang E.T., Gregersen H., Porwit-MacDonald A., et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006, 98(January (1)):51-60.
16. Ekström Smedby K., Vajdic C.M., Falster M., Engels E.A., Martínez-Maza O., Turner J., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008, 111(April (8)):4029-4038. [Epub 2008 February 8]. 10.1182/blood-2007-10-119974.
17. Risselada A.P., Kruize A.A., Bijlsma J.W. Clinical features distinguishing lymphoma development in primary Sjögren's syndrome-A retrospective cohort study. Semin Arthritis Rheum 2013, 43(October (2)):171-177. [Epub 2013 May 7]. 10.1016/j.semarthrit.2013.03.001.
18. Voulgarelis M., Dafni U.G., Isenberg D.A., Moutsopoulos H.M. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999, 42(August (8)):1765-1772.
19. Theander E., Henriksson G., Ljungberg O., Mandl T., Manthorpe R., Jacobsson L.T.H. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65:796-803.
20. Baimpa E., Dahabreh I.J., Voulgarelis M., Moursopoulos H.M. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 2009, 88(September (5)):284-293.
21. Solans-Laqué R., López-Hernandez A., Bosch-Gil J.A., Palacios A., Campillo M., Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 2011, 41(December (3)):415-423.
22. Quartuccio L., Isola M., Baldini C., Priori R., Bartoloni Bocci E., Carubbi F., et al. Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 2013, (November). pii:S0896-8411(13)00134-0 [Epub ahead of print]. 10.1016/j.jaut.2013.10.002.
23. Ramos-Casals M., Brito-Zerón P., Perez-DE-Lis M., Diaz-Lagares C., Bove A., Soto M.J., et al. Clinical and prognostic significance of parotid scintigraphy in 405 patients with primary Sjogren's syndrome. J Rheumatol 2010, 37(March (3)):585-590. [Epub 2010 January 15]. 10.3899/jrheum.090835.
24. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 2011, 70(August (8)):1363-1368.
25. Voulgarelis M., Ziakas P.D., Papageorgiou A., Baimpa E., Tzioufas A.G., Moutsopoulos H.M. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore) 2012, 91(January (1)):1-9. 10.1097/MD.0b013e31824125e4.
26. Lebwohl B., Granath F., Ekbom A., Smedby K.E., Murray J.A., Neugut A.I., et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med 2013, 159(August (3)):169-175. 10.7326/0003-4819-159-3-201308060-00006.
27. Holmes G.K., Prior P., Lane M.R., Pope D., Allan R.N. Malignancy in coeliac disease - effect of a gluten free diet. Gut 1989, 30(March (3)):333-338.
28. Silano M., Volta U., Vincenzi A.D., Dessì M., Vincenzi M.D. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci 2008, 53(April (4)):972-976. Collaborating Centers of the Italian Registry of the Complications of Coeliac Disease, [Epub 2007 October 13].
29. Askling J., Linet M., Gridley G., Halstensen T.S., Ekström K., Ekbom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002, 123(November (5)):1428-1435.
30. Gao Y., Kristinsson S.Y., Goldin L.R., Björkholm M., Caporaso N.E., Landgren O. Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology 2009, 136(January (1)):91-98. [Epub 2008 September 25]. 10.1053/j.gastro.2008.09.031.
31. Olén O., Askling J., Ludvigsson J.F., Hildebrand H., Ekbom A., Smedby K.E. Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtype. Dig Liver Dis 2011, 43(November (11)):862-868. [Epub 2011 August 30]. 10.1016/j.dld.2011.07.012.
32. Smedby K.E., Akerman M., Hildebrand H., Glimelius B., Ekbom A., Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005, 54(January (1)):54-59.
33. Tio M., Cox M.R., Eslick G.D. Meta-analysis: coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy. Aliment Pharmacol Ther 2012, 35(March (5)):540-551. [Epub 2012 January 13]. 10.1111/j.1365-2036.2011.04972.x.
34. Hoshida Y., Xu J.X., Fujita S., Nakamichi I., Ikeda J., Tomita Y., et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007, 34(February (2)):322-331. [Epub 2006 November 15].
35. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68(July (7)):1100-1104. [Epub 2008 December 5, Review]. 10.1136/ard.2008.093690.
36. Kandiel A., Fraser A.G., Korelitz B.I., Brensinger C., Lewis J.D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54(August (8)):1121-1125.
37. Lopez-Olivo M.A., Tayar J.H., Martinez-Lopez J.A., Pollono E.N., Cueto J.P., Gonzales-Crespo M.R., et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012, 308(September (9)):898-908. 10.1001/2012.jama.10857.
38. Deepak P., Sifuentes H., Sherid M., Stobaugh D., Sadozai Y., Ehrenpreis E.D. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-a) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013, 108(January (1)):99-105. [Epub 2012 October 2]. 10.1038/ajg.2012.334.
39. Urayama K.Y., Jarrett R.F., Hjalgrim H., Diepstra A., Kamatani Y., Chabrier A., et al. Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst 2012, 104(February (3)):240-253. [Epub 2012 January 27]. 10.1093/jnci/djr516.
40. Conde L., Halperin E., Akers N.K., Brown K.M., Smedby K.E., Rothman N., et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 2010, 42(August (8)):661-664. [Epub 2010 July 18]. 10.1038/ng.626.
41. Smedby K.E., Foo J.N., Skibola C.F., Darabi H., Conde L., Hjalgrim H., et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011, 7(April (4)):e1001378. [Epub 2011 April 21]. 10.1371/journal.pgen.1001378.
42. Ekström K., Hjalgrim H., Brandt L., Baecklund E., Klareskog L., Ekbom A., et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003, 48:963-970.
43. Mellemkjaer L., Pfeiffer R.M., Engels E.A., Gridley G., Wheeler W., Hemminki K., et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum 2008, 58(March (3)):657-666. 10.1002/art.23267.
44. Lundberg K., Bengtsson C., Kharlamova N., Reed E., Jiang X., Kallberg H., et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis 2013, 72(May (5)):652-658. [Epub 2012 June 1]. 10.1136/annrheumdis-2012-201484.
45. Ekblom-Kullberg S., Kautiainen H., Alha P., Leirisalo-Repo M., Julkunen H. Smoking and the risk of systemic lupus erythematosus. Clin Rheumatol 2013, 32(August (8)):1219-1222. [Epub 2013 March 21]. 10.1007/s10067-013-2224-4.
46. Karabulut G., Kitapcioglu G., Inal V., Kalfa M., Yargucu F., Keser G., et al. Cigarette smoking in primary Sjögren's syndrome: positive association only with ANA positivity. Mod Rheumatol 2011, 21(December (6)):602-607. [Epub 2011 March 30]. 10.1007/s10165-011-0446-3.
47. Ludvigsson J.F., Montgomery S.M., Ekbom A. Smoking and celiac disease: a population-based cohort study. Clin Gastroenterol Hepatol 2005, 3(September (9)):869-874.
48. Wiersinga W.M. Smoking and thyroid. Clin Endocrinol (Oxf) 2013, 79(August (2)):145-151. [Epub 2013 May 11]. 10.1111/cen.12222.
49. Gibson T.M., Smedby K.E., Skibola C.F., Hein D.W., Slager S.L., de Sanjosé S., et al. Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes Control 2013, 24(January (1)):125-134. [Epub 2012 November 18]. 10.1007/s10552-012-0098-4.
50. Sergentanis T.N., Kanavidis P., Michelakos T., Petridou E.T. Cigarette smoking and risk of lymphoma in adults: a comprehensive meta-analysis on Hodgkin and non-Hodgkin disease. Eur J Cancer Prev 2013, 22(March (2)):131-150. 10.1097/CEJ.0b013e328355ed08.
51. Kamel O.W., Holly E.A., van de Rijn M., Lele C., Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999, 26(August (8)):1676-1680.
52. Royer B., Cazals-Hatem D., Sibilia J., Agbalika F., Cayuela J.M., Soussi T., et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997, 90(July (2)):766-775.
53. Hirose Y., Sugai S., Masaki Y., Ogawa Y., Takeshita S., Kin C., et al. Epstein-Barr virus study in malignant lymphoma in Sjögren's syndrome. Int J Hematol 1999, 69(April (3)):174-179.
54. Dawson T.M., Starkebaum G., Wood B.L., Willkens R.F., Gown A.M. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren's syndrome: case series. J Rheumatol 2001, 28(January (1)):47-53.
55. Ilyas M., Niedobitek G., Agathanggelou A., Barry R.E., Read A.E., Tierney R., et al. Non-Hodgkin's lymphoma, coeliac disease, and Epstein-Barr virus: a study of 13 cases of enteropathy-associated T- and B-cell lymphoma. J Pathol 1995, 177(October (2)):115-122.
56. Walsh S.V., Egan L.J., Connolly C.E., Stevens F.M., Egan E.L., McCarthy C.F. Enteropathy-associated T-cell lymphoma in the West of Ireland: low-frequency of Epstein-Barr virus in these tumors. Mod Pathol 1995, 8(September (7)):753-757.
57. Lam K.Y., Lo C.Y., Kwong D.L., Lee J., Srivastava G. Malignant lymphoma of the thyroid. A 30-year clinicopathologic experience and an evaluation of the presence of Epstein-Barr virus. Am J Clin Pathol 1999, 112(August (2)):263-270.
58. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman (Eds.).
59. Ichikawa A., Arakawa F., Kiyasu J., Sato K., Miyoshi H., Niino D., et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 2013, 91(July (1)):20-28. [Epub 2013 May 13]. 10.1111/ejh.12116.
60. Huh J. Epidemiologic overview of malignant lymphoma. Korean J Hematol 2012, 47(June (2)):92-104. [Epub 2012 June 26]. 10.5045/kjh.2012.47.2.92.
61. Vos A.C., Bakkal N., Minnee R.C., Casparie M.K., de Jong D.J., Dijkstra G., et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2011, 17(September (9)):1837-1845. [Epub 2010 December 22]. 10.1002/ibd.21582.
62. Rosenquist R., Davi F., Stamatopoulos K. Antigens in lymphoma development-Current knowledge and future directions. Semin Cancer Biol 2013, 23(December (6)):397-398. [Epub 2013 September 27]. 10.1016/j.semcancer.2013.09.003.
63. Sutton L.A., Agathangelidis A., Belessi C., Darzentas N., Davi F., Ghia P., et al. Antigen selection in B-cell lymphomas-tracing the evidence. Semin Cancer Biol 2013, 23(December (6)):399-409. [Epub 2013 August 8]. 10.1016/j.semcancer.2013.07.006.
64. Niemann C.U., Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013, 23(December (6)):410-421. [Epub 2013 September 20]. 10.1016/j.semcancer.2013.09.001.
65. Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005, 5(April (4)):251-262.
66. Shaffer A.L., Rosenwald A., Staudt L.M. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002, 2(December (12)):920-932.
67. Ferreri A.J., Govi S., Ponzoni M. Marginal zone lymphomas and infectious agents. Semin Cancer Biol 2013, 23(December (6)):431-440. [Epub 2013 September 30]. 10.1016/j.semcancer.2013.09.004.
68. Dolcetti R., Dal Col J., Martorelli D., Carbone A., Klein E. Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. Semin Cancer Biol 2013, 23(December (6)):441-456. [Epub 2013 August 3]. 10.1016/j.semcancer.2013.07.005.
69. Gloghini A., Dolcetti R., Carbone A. Lymphomas occurring specifically in HIV-infected patients: from pathogenesis to pathology. Semin Cancer Biol 2013, 23(December (6)):457-467. [Epub 2013 August 30]. 10.1016/j.semcancer.2013.08.004.
70. Wang M.L., Rule S., Martin P., Goy A., Auer R., Kahl B.S., et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013, 369(August (6)):507-516. [Epub 2013 June 19]. 10.1056/NEJMoa1306220.
71. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369(July (1)):32-42. [Epub 2013 June 19]. 10.1056/NEJMoa1215637.
72. Youinou P., Devauchelle-Pensec V., Pers J.O. Significance of B cells and B cell clonality in Sjögren's syndrome. Arthritis Rheum 2010, 62(September (9)):2605-2610. [Review]. 10.1002/art.27564.
73. Cornec D., Devauchelle-Pensec V., Tobón G.J., Pers J.O., Jousse-Joulin S., Saraux A. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun 2012, 39(September (3)):161-167. [Epub 2012 June 30, Review]. 10.1016/j.jaut.2012.05.014.
74. Bahler D.W., Swerdlow S.H. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 1998, 91(March (6)):1864-1872.
75. Guzmán L.M., Castillo D., Aguilera S.O. Polymerase chain reaction (PCR) detection of B cell clonality in Sjögren's syndrome patients: a diagnostic tool of clonal expansion. Clin Exp Immunol 2010, 161(July (1)):57-64. [Epub 2010 April 9]. 10.1111/j.1365-2249.2010.04144.x.
76. -/low B cells in Sjögren's syndrome-associated lymphoproliferation. Arthritis Rheum 2013, 65(April (4)):1085-1096. 10.1002/art.37828.
77. Bahler D.W., Miklos J.A., Swerdlow S.H. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 1997, 89(May (9)):3335-3344.
78. Berg A.R., Weisenburger D.D., Linder J., Armitage J.O. Lymphoplasmacytic lymphoma. Report of a case with three monoclonal proteins derived from a single neoplastic clone. Cancer 1986, 57(May (9)):1794-1797.
79. Martin T., Weber J.C., Levallois H., Labouret N., Soley A., Koenig S., et al. Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 2000, 43(April (4)):908-916.
80. Miklos J.A., Swerdlow S.H., Bahler D.W. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000, 95(June (12)):3878-3884.
81. Bende R.J., Aarts W.M., Riedl R.G., de Jong D., Pals S.T., van Noesel C.J. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005, 201(April (8)):1229-1241.
82. Jordan R., Diss T.C., Lench N.J., Isaacson P.G., Speight P.M. Immunoglobulin gene rearrangements in lymphoplasmacytic infiltrates of labial salivary glands in Sjögren's syndrome. A possible predictor of lymphoma development. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995, 79(June (6)):723-729.
83. De Vita S., Boiocchi M., Sorrentino D., Carbone A., Avellini C., Dolcetti R., et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome. Arthritis Rheum 1997, 40(February (2)):318-331.
84. Hansen A., Reiter K., Pruss A., Loddenkemper C., Kaufmann O., Jacobi A.M., et al. Dissemination of a Sjögren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements. Arthritis Rheum 2006, 54(January (1)):127-137.
85. Gasparotto D., De Vita S., De Re V., Marzotto A., De Marchi G., Scott C.A., et al. Extrasalivary lymphoma development in Sjögren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum 2003, 48(November (11)):3181-3186.
86. Dong L., Chen Y., Masaki Y., Okazaki T., Umehara H. Possible mechanisms of lymphoma development in Sjögren's syndrome. Curr Immunol Rev 2013, 9(February (1)):13-22.
87. Quartuccio L., Salvin S., Fabris M., Maset M., Pontarini E., Isola M., et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013, 52(February (2)):276-281. [Epub 2012 August 9]. 10.1093/rheumatology/kes180.
88. Tobón G.J., Saraux A., Gottenberg J.E., Quartuccio L., Fabris M., Seror R., et al. The FMS-like tyrosine kinase 3-ligand may be biological marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 2013, (August). [Epub ahead of print]. 10.1002/art.38129.
89. Chanudet E., Huang Y., Zeng N., Streubel B., Chott A., Raderer M., et al. TNFAIP3 abnormalities in MALT lymphoma with autoimmunity. Br J Haematol 2011, 154(August (4)):535-539. [Epub 2011 April 26]. 10.1111/j.1365-2141.2011.08624.x.
90. Nocturne G., Boudaoud S., Miceli-Richard C., Viengchareun S., Lazure T., Nititham J., et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 2013, (November). [Epub ahead of print].
91. Cellier C., Delabesse E., Helmer C., Patey N., Matuchansky C., Jabri B., et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000, 356(July (9225)):203-208.
92. Malamut G., Afchain P., Verkarre V., Lecomte T., Amiot A., Damotte D., et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009, 136(January (1)):81-90. [Epub 2008 October 7]. 10.1053/j.gastro.2008.09.069.
93. Malamut G., Meresse B., Cellier C., Cerf-Bensussan N. Refractory celiac disease: from bench to bedside. Semin Immunopathol 2012, 34(July (4)):601-613. [Epub 2012 July 19, Review]. 10.1007/s00281-012-0322-z.
94. Malamut G., Verkarre V., Callens C., Colussi O., Rahmi G., MacIntyre E., et al. Enteropathy-associated T-cell lymphoma complicating an autoimmune enteropathy. Gastroenterology 2012, 142(April (4)). 726-729.e3; quiz e13-4 [Epub 2012 January 4]. 10.1053/j.gastro.2011.12.040.
95. Stein S.A., Wartofsky L. Primary thyroid lymphoma: a clinical review. J Clin Endocrinol Metab 2013, 98(August (8)):3131-3138. [Epub 2013 May 28]. 10.1210/jc.2013-1428.
96. Moshynska O.V., Saxena A. Clonal relationship between Hashimoto thyroiditis and thyroid lymphoma. J Clin Pathol 2008, 61(April (4)):438-444. [Epub 2007 November 15].
97. Sato Y., Nakamura N., Nakamura S., Sakugawa S., Ichimura K., Tanaka T., et al. Deviated VH4 immunoglobulin gene usage is found among thyroid mucosa-associated lymphoid tissue lymphomas, similar to the usage at other sites, but is not found in thyroid diffuse large B-cell lymphomas. Mod Pathol 2006, 19(December (12)):1578-1584. [Epub 2006 September 15].
98. Sanchez-Gonzalez B., Garcia M., Montserrat F., Sanchez M., Angona A., Solano A., et al. Diffuse large B-cell lymphoma associated with chronic inflammation in metallic implant. J Clin Oncol 2013, 31(April (10)):e148-e151. [Epub 2013 February 11]. 10.1200/JCO.2012.42.8250.
99. Loong F., Chan A.C., Ho B.C., Chau Y.P., Lee H.Y., Cheuk W., et al. Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios. Mod Pathol 2010, 23(April (4)):493-501. [Epub 2010 January 8]. 10.1038/modpathol.2009.168.
100. Boroumand N., Ly T.L., Sonstein J., Medeiros L.J. Microscopic diffuse large B-cell lymphoma (DLBCL) occurring in pseudocysts: do these tumors belong to the category of DLBCL associated with chronic inflammationα. Am J Surg Pathol 2012, 36(July (7)):1074-1080. 10.1097/PAS.0b013e3182515fb5.
101. Baecklund E., Backlin C., Iliadou A., Granath F., Ekbom A., Amini R.-M., et al. Characteristics of diffuse large B-cell lymphomas in rheumatoid arthritis. Arthritis Rheum 2006, 54:3774-4378.
102. Baecklund E., Natkunam Y., Backlin C., Askling J., Ekbom A., Feltelius N., et al. Expression of the human germinal-center associated lymphoma (HGAL) protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. Br J Haematol 2008, 141:69-72.
103. Boissier M.C., Semerano L., Challal S., Saidenberg-Kermanac'h N., Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 2012, 39(September (3)):222-228. [Epub 2012 June 16]. 10.1016/j.jaut.2012.05.021.
104. Löfström B., Backlin C., Pettersson T., Lundberg I.E., Baecklund E. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2011, 38:1891-1897. [Epub ahead of print].
105. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463(January (7277)):88-92. 10.1038/nature08638.
106. Pasqualucci L., Trifonov V., Fabbri G., Ma J., Rossi D., Chiarenza A., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011, 43(July (9)):830-837. 10.1038/ng.892.
107. Rossi D., Ciardullo C., Gaidano G. Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies. Semin Cancer Biol 2013, 23(December (6)):422-430. [Epub 2013 May 8]. 10.1016/j.semcancer.2013.04.002.
108. Young R.M., Staudt L.M. A new "brew" of MALT1 inhibitors. Cancer Cell 2012, 22(December (6)):706-707. 10.1016/j.ccr.2012.11.011.
109. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470(February (7332)):115-119. [Epub 2010 December 22]. 10.1038/nature09671.
110. Lohr J.G., Stojanov P., Lawrence M.S., Auclair D., Chapuy B., Sougnez C., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012, 109(March (10)):3879-3884. [Epub 2012 February 17]. 10.1073/pnas.1121343109.
111. Neri R., Giorgetti M., Zampa V., Iacopetti V., Vannucci P., Tognetti A., et al. Case report. Elbow monoarthritis revealing B cell non-Hodgkin's lymphoma. Clin Rheumatol 2013, 32(March (Suppl. 1)):S111-S114. [Epub 2010 October 13]. 10.1007/s10067-010-1578-0.
112. van Baarsen L.G., de Hair M.J., Ramwadhdoebe T.H., Zijlstra I.J., Maas M., Gerlag D.M., et al. The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis. Ann Rheum Dis 2013, 72(August (8)):1420-1424. [Epub 2013 May 9]. 10.1136/annrheumdis-2012-202990.
113. Dörner T., Lipsky P.E. B cells: depletion or functional modulation in rheumatic diseases. Curr Opin Rheumatol 2013, (October). [Epub ahead of print].
114. Robak T., Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs 2012, 21(July (7)):921-947. [Epub 2012 May 22, Review]. 10.1517/13543784.2012.685650.
115. Hellgren K., Iliadou A., Rosenquist R., Feltelius N., Backlin C., Enblad G., et al. Rheumatoid arthritis, treatment with corticosteroids, and risk of malignant lymphomas. Ann Rheum Dis 2010, 69:654-659.
116. Leandro M.J. Becerra-Fernandez E.B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011, 25(August (4)):535-548. 10.1016/j.berh.2011.10.005.
117. Vossenkämper A., Lutalo P.M., Spencer J. Translational mini-review series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol 2012, 167(January (1)):7-14. [Review]. 10.1111/j.1365-2249.2011.04460.x.
118. Sluzevich J.C., Hall M.R., Roy V. Subcutaneous panniculitis-like T-cell lymphoma after rituximab. J Am Acad Dermatol 2012, 67(November (5)):e223-e225. 10.1016/j.jaad.2012.04.023.
119. Quartuccio L., Fabris M., Moretti M., Barone F., Bombardieri M., Rupolo M., et al. Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2008, 2:38-43. [Epub 2008 May 28]. 10.2174/1874312900802010038.
120. Anderson L.A., Gadalla S., Morton L.M., Landgren O., Pfeiffer R., Warren J.L., et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009, 125(July (2)):398-405.
121. Askling J., Baecklund E., Granath F., Geborek P., Fored M., Backlin C., et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68(May (5)):648-653.
122. Parikh-Patel A., White R.H., Allen M., Cress R. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009, 20(August (6)):1001-1010.
123. Mercer L.K., Davies R., Galloway J.B., Low A., Lunt M., Dixon W.G., et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 2013, 52(January (1)):91-98.
124. Dreyer L., Mellemkjær L., Andersen A.R., Bennett P., Poulsen U.E., Juulsgaard Ellingsen T., et al. Incidences of overall and site specific cancers in TNFa inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013, 72(January (1)):79-82.
125. Zhang W., Feng S., Yan S., Zhao Y., Li M., Sun J., et al. Incidence of malignancy in primary Sjogren's syndrome in a Chinese cohort. Rheumatology (Oxford) 2010, 49(March (3)):571-577.
126. Weng M.Y., Huang Y.T., Liu M.F., Lu T.H. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan. Ann Rheum Dis 2012, 71(April (4)):524-527. [Epub 2011 November 9]. 10.1136/annrheumdis-2011-200402.
127. Johnsen S.J., Brun J.G., Gøransson L.G., Småstuen M.C., Johannesen T.B., Haldorsen K., et al. Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study. Arthritis Care Res (Hoboken) 2013, 65(May (5)):816-821. 10.1002/acr.21887.
128. Liang Y., Yang Z., Qin B., Zhong R. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 2013, (May). [Epub ahead of print].
129. Kang K.Y., Kim H.O., Yoon H.S., Lee J., Lee W.C., Ko H.J., et al. Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 2010, 29(April (4)):381-388. [Epub 2009 December 30]. 10.1007/s10067-009-1332-7.
130. Chen Y.-J., Chang Y.-T., Wang C.-B., Wu C.-Y. Malignancy in systemic lupus erythematosus: a Nationwide Cohort Study in Taiwan. Am J Med 2010, 123(12):1150.e1-1150.e6.
131. Dreyer L., Faurschou M., Mogensen M., Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum 2011, 63(October (10)):3032-3037. 10.1002/art.30483.
132. Bernatsky S., Ramsey-Goldman R., Labrecque J., Joseph L., Boivin J.F., Petri M., et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013, 42(May):130-135. [Epub 2013 February 12]. 10.1016/j.jaut.2012.12.009.
133. Elfström P., Granath F., Ekström Smedby K., Montgomery S.M., Askling J., Ekbom A., et al. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. Natl Cancer Inst 2011, 103(March (5)):436-444. [Epub 2011 February 2]. 10.1093/jnci/djq564.
134. Grainge M.J., West J., Solaymani-Dodaran M., Card T.R., Logan R.F. The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther 2012, 35(March (6)):730-739. [Epub 2012 January 30]. 10.1111/j.1365-2036.2012.04998.x.
135. Leslie L.A., Lebwohl B., Neugut A.I., Gregory Mears J., Bhagat G., Green P.H. Incidence of lymphoproliferative disorders in patients with celiac disease. Am J Hematol 2012, 87(August (8)):754-759. [Epub 2012 May 28]. 10.1002/ajh.23237.